NO20091203L - Sensibilisering av tumorceller for stralebehandling gjennom administrasjonen av endotelinagonister - Google Patents

Sensibilisering av tumorceller for stralebehandling gjennom administrasjonen av endotelinagonister

Info

Publication number
NO20091203L
NO20091203L NO20091203A NO20091203A NO20091203L NO 20091203 L NO20091203 L NO 20091203L NO 20091203 A NO20091203 A NO 20091203A NO 20091203 A NO20091203 A NO 20091203A NO 20091203 L NO20091203 L NO 20091203L
Authority
NO
Norway
Prior art keywords
administration
tumor cells
radiation therapy
sensitization
endothelin agonists
Prior art date
Application number
NO20091203A
Other languages
English (en)
Norwegian (no)
Inventor
Anil Gulati
Luigi Lenaz
Guru Reddy
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of NO20091203L publication Critical patent/NO20091203L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20091203A 2006-08-31 2009-03-23 Sensibilisering av tumorceller for stralebehandling gjennom administrasjonen av endotelinagonister NO20091203L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82419706P 2006-08-31 2006-08-31
PCT/US2007/076903 WO2008027839A1 (fr) 2006-08-31 2007-08-27 Sensibilisation de cellules tumorales à la radiothérapie par administration d'agonistes d'endothéline

Publications (1)

Publication Number Publication Date
NO20091203L true NO20091203L (no) 2009-03-23

Family

ID=38920900

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091203A NO20091203L (no) 2006-08-31 2009-03-23 Sensibilisering av tumorceller for stralebehandling gjennom administrasjonen av endotelinagonister

Country Status (15)

Country Link
US (2) US8394757B2 (fr)
EP (1) EP2059254B1 (fr)
JP (1) JP5306208B2 (fr)
KR (1) KR101547361B1 (fr)
CN (1) CN101534852B (fr)
BR (1) BRPI0722292A2 (fr)
CA (1) CA2661833C (fr)
DK (1) DK2059254T3 (fr)
ES (1) ES2541657T3 (fr)
IL (1) IL197335A (fr)
MX (1) MX2009002308A (fr)
NO (1) NO20091203L (fr)
RU (1) RU2009111605A (fr)
WO (1) WO2008027839A1 (fr)
ZA (1) ZA200901425B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
EP2059254B1 (fr) 2006-08-31 2015-04-08 Spectrum Pharmaceuticals, Inc. Sensibilisation de cellules tumorales à la radiothérapie par administration d'agonistes d'endothéline
AU2008297566A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2010017332A2 (fr) * 2008-08-07 2010-02-11 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Radioprotecteurs ciblant la thrombospondine-1 et cd47
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
CA2999234A1 (fr) 2015-09-25 2017-03-30 Nippon Kayaku Kabushiki Kaisha Compose azoique, composition d'encre, procede d'impression par jet d'encre et article colore

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112954A (en) * 1988-02-26 1992-05-12 Neorx Corporation Method of enhancing the effect of cytotoxic agents
US5550110A (en) 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
CA2135151A1 (fr) 1993-11-08 1995-05-09 Mitsuhiro Wakimasu Hexapeptides cycliques, leur production et leur utilisation
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
AU686018B2 (en) 1994-09-20 1998-01-29 Amcor Packaging (New Zealand) Limited A container
MX9703988A (es) 1994-12-12 1998-02-28 Omeros Med Sys Inc SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO.
US6251861B1 (en) 1996-06-27 2001-06-26 Takeda Chemical Industries, Ltd. Treatment of cerebral infarction using cyclic hexapeptides
CA2268640A1 (fr) 1998-04-14 1999-10-14 Mitsuru Shiraishi Composition pour la prevention ou le traitement de maladies ischemiques
ATE225655T1 (de) * 1998-09-25 2002-10-15 Warner Lambert Co Chemotherapie des krebses mit acetyldinalin in verbindung mit gemcitabin, capecitabin oder cisplatin
GB9910155D0 (en) 1999-04-30 1999-06-30 Microbiological Research Agenc Augmented agglutination assay
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
CA2409927A1 (fr) 2000-05-31 2001-12-06 Warner-Lambert Company Combinaisons d'un antagoniste de recepteur d'endotheline et compose anti-epileptique presentant des proprietes analgesiques ou de soulagement de la douleur
US6573285B2 (en) 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
WO2003009805A2 (fr) 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Methodes analgesiques utilisant des ligands des recepteurs de l'endotheline
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US20030229004A1 (en) * 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
WO2004037235A2 (fr) * 2002-10-24 2004-05-06 The Board Of Trustees Of The University Of Illinois Methode et composition destinees a la prevention de l'apparition et au traitement de tumeurs solides
US8217010B2 (en) 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
WO2006057988A2 (fr) * 2004-11-22 2006-06-01 The Board Of Trustees Of The University Of Illinois Utilisation diagnostique d'agonistes du recepteur de l'endotheline etb et d'antagonistes du recepteur eta dans l'imagerie de tumeurs
WO2006091767A2 (fr) 2005-02-22 2006-08-31 Spectrum Pharmaceuticals, Inc. Methodes, compositions et articles manufactures destines a contribuer au traitement de tumeurs solides
EP2059254B1 (fr) 2006-08-31 2015-04-08 Spectrum Pharmaceuticals, Inc. Sensibilisation de cellules tumorales à la radiothérapie par administration d'agonistes d'endothéline

Also Published As

Publication number Publication date
IL197335A (en) 2013-07-31
ES2541657T3 (es) 2015-07-23
US8394757B2 (en) 2013-03-12
US8957014B2 (en) 2015-02-17
WO2008027839A1 (fr) 2008-03-06
EP2059254B1 (fr) 2015-04-08
CN101534852A (zh) 2009-09-16
MX2009002308A (es) 2009-09-07
DK2059254T3 (en) 2015-07-13
RU2009111605A (ru) 2010-10-10
ZA200901425B (en) 2010-04-28
KR101547361B1 (ko) 2015-08-25
CN101534852B (zh) 2013-02-13
IL197335A0 (en) 2011-08-01
JP5306208B2 (ja) 2013-10-02
EP2059254A1 (fr) 2009-05-20
US20130150649A1 (en) 2013-06-13
BRPI0722292A2 (pt) 2014-04-15
CA2661833A1 (fr) 2008-03-06
US20080318846A1 (en) 2008-12-25
JP2010502638A (ja) 2010-01-28
CA2661833C (fr) 2016-01-26
KR20090069279A (ko) 2009-06-30

Similar Documents

Publication Publication Date Title
NO20091203L (no) Sensibilisering av tumorceller for stralebehandling gjennom administrasjonen av endotelinagonister
CY1122812T1 (el) Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p
EA201391351A1 (ru) Способы повышения эффективности folr1 терапии рака
CY1118187T1 (el) Χημικες ενωσεις
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
ES2583010T3 (es) Nuevos inhibidores de la ruta de Stat3 e inhibidores de células madre del cáncer
CL2008003035A1 (es) Uso de un anticuerpo anti cd-20 de tipo 2 que sirve para preparar un medicamento, que en conjunto con un agente activo anti-bcl-2, permite tratar un cancer que exprese el cd 20.
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
UA108618C2 (uk) Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CL2008002129A1 (es) Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer.
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
CR20110553A (es) Terapia complementaria contra el cáncer
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
NO20092725L (no) Quinazoliner for PDK1 inhibering
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CL2008003041A1 (es) Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
EA201100612A1 (ru) Новые производные 2-амидотиадиазола
EA200870148A1 (ru) Производные сулиндака, их применение и получение
ECSP14019113A (es) Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina
CY1121859T1 (el) Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης
DOP2012000260A (es) Uso de nuevos inhibidores de pan–cdk para tratar tumores
NO20065231L (no) Nye imidazoler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application